Metoprolol Succinate ER — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for High Blood Pressure

• Amlodipine
• Lisinopril
• Losartan
• Atenolol
• Diltiazem ER
• Hydrochlorothiazide

About Metoprolol succinate (ER)

Metoprolol succinate extended-release (ER) is a widely prescribed medication crucial for managing various heart conditions. As a long-acting beta-blocker, it plays a vital role in maintaining cardiovascular health. At TheDrugClub, we understand the importance of consistent medication access, which is why we're dedicated to making essential prescriptions like metoprolol succinate ER incredibly affordable for our members.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Metoprolol Succinate ER is approved for (FDA label)

Metoprolol succinate, is a beta-adrenergic blocker indicated for the treatment of: • Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Angina Pectoris. ( 1.2 ) • Heart Failure, to reduce the risk of cardiovascular mortality and heart failure hospitalizations in patients with heart failure ( 1.3 ) 1.1 Hypertension Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol.

Source: Read the full FDA label on DailyMed. Label effective date: August 31, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Metoprolol Succinate ER (FDA label)

Metoprolol Succinate Extended-Release Tablets, USP are available containing 23.75 mg of metoprolol succinate, USP equivalent to 25 mg of metoprolol tartrate, USP. 25 mg tablets: White to off white, oval shape, biconvex film coated tablet with breakline on one side and debossed with 'A' and '3' on each side of breakline on other side. Metoprolol succinate extended-release tablets: 25 mg. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 76c69d7c-e90c-4f96-a45b-e9dad9444263. SPL document ID: 5a581516-790d-fecd-e063-6394a90aca27. Label effective date: August 31, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Metoprolol Succinate ER (FDA label)

The following adverse reactions are described elsewhere in labeling: • Worsening angina or myocardial infarction [see Warnings and Precautions (5) ] • Worsening heart failure [see Warnings and Precautions (5) ]. • Worsening AV block [see Contraindications (4) ]. • Most common adverse reactions: tiredness, dizziness, depression, shortness of breath, bradycardia, hypotension, diarrhea, pruritus, rash. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Ascend Laboratories, LLC at 1-877-272-7901 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 76c69d7c-e90c-4f96-a45b-e9dad9444263. SPL document ID: 5a581516-790d-fecd-e063-6394a90aca27. Label effective date: August 31, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Metoprolol Succinate ER (FDA label)

Metoprolol succinate extended-release tablets are contraindicated in severe bradycardia, second- or third- degree heart block, cardiogenic shock, decompensated heart failure, sick sinus syndrome (unless a permanent pacemaker is in place), and in patients who are hypersensitive to any component of this product. • Known hypersensitivity to product components. ( 4 ) • Severe bradycardia: Greater than first degree heart block, or sick sinus syndrome without a pacemaker. ( 4 ) • Cardiogenic shock or decompensated heart failure. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 76c69d7c-e90c-4f96-a45b-e9dad9444263. SPL document ID: 5a581516-790d-fecd-e063-6394a90aca27. Label effective date: August 31, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Metoprolol Succinate ER (FDA label)

• Abrupt cessation may exacerbate myocardial ischemia. ( 5.1 ) • Heart Failure: Worsening cardiac failure may occur. ( 5.2 ) • Bronchospastic Disease: Avoid beta-blockers. ( 5.3 ) • Concomitant use of glycosides, clonidine, diltiazem and verapamil with beta-blockers can increase the risk of bradycardia. ( 5.4 ) • Pheochromocytoma: Initiate therapy with an alpha-blocker. ( 5.5 ) • Major Surgery: Avoid initiation of high-dose extended-release metoprolol in patients undergoing non-cardiac surgery.

Source: FDA prescribing information (DailyMed). Set ID: 76c69d7c-e90c-4f96-a45b-e9dad9444263. SPL document ID: 5a581516-790d-fecd-e063-6394a90aca27. Label effective date: August 31, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Metoprolol Succinate ER (FDA label)

• Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents. ( 7.1 ) • CYP2D6 Inhibitors are likely to increase metoprolol concentration. ( 7.2 ) • Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. ( 7.3 ) 7.1 Catecholamine Depleting Drugs Catecholamine depleting drugs (e.g., reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with metoprolol succinate extended-release tablets plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 7.2 CYP2D6 Inhibitors Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. While there is no information about moderate or weak inhibitors, these too are likely to increase metoprolol concentration.

Source: FDA prescribing information (DailyMed). Set ID: 76c69d7c-e90c-4f96-a45b-e9dad9444263. SPL document ID: 5a581516-790d-fecd-e063-6394a90aca27. Label effective date: August 31, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.